Protara Therapeutics starts Phase 3 trial for IV Choline Chloride in cancer patients.

Protara Therapeutics has initiated its Phase 3 THRIVE-3 clinical trial to evaluate IV Choline Chloride in patients receiving long-term parenteral support. The trial aims to address choline deficiency, which affects 78% of patients on PS and can lead to serious hepatic injury, neuropsychological impairment, muscle damage, and thrombotic abnormalities. IV Choline Chloride has been granted Fast Track designation by the FDA.